September 2021
Sanford Burnham Prebys and the Salk Institute license ULK1/2 inhibitors to Endeavor BioMedicines for the treatment of cancer

"This agreement with Endeavor BioMedicines moves our efforts closer to our goal of helping people living with cancer," says Nicholas Cosford, Ph.D., professor and deputy director of our NCI-designated Cancer Center. Cosford, along with Reuben Shaw, Ph.D., professor at the Salk Institute, pioneered early research on the ULK1/2 pathway in cancer. Endeavor plans to complete IND-enabling studies and advance the ULK1/2 program into the clinic for colorectal and lung cancers in the next 18 months.

Peter Adams awarded $13 million to study link between aging and liver cancer

“If we can understand why the incidence of liver cancer increases with age, that gives us more opportunity for detecting, treating and preventing this type of cancer," says Peter Adams, Ph.D., who leads the five-year NIH-funded project with Salk Institute professor Gerald Shadel, Ph.D.

Jamey Marth awarded $13.5 million to advance research on sepsis

"The need for early diagnosis and better sepsis treatment is critical," says Jamey Marth, Ph.D. The five-year NIH award supports the continuation of his team's groundbreaking research aimed to improve treatment options for this often-deadly syndrome.

Karen Ocorr awarded $2 million from NASA to study the effects of low gravity

"Getting a precise understanding of how altered gravity impacts muscles and neurons puts us one step closer to understanding how to sustain human life in space," says Karen Ocorr, Ph.D. The award will fund a three-year project to study the effects of low gravity on fruit flies and nematode worms, which have much the same biological makeup as humans.

Chemical biologist Eric Wang joins Sanford Burnham Prebys 

“I’m thrilled to be joining such esteemed faculty and am looking forward to uncovering new therapeutic approaches for cancer," says Eric Wang, Ph.D. As an assistant professor in our NCI-designated Cancer Center, Wang will focus on developing chemical tools that target vulnerabilities in tumor cells or reprogram immune cells to fight cancer.

Acute myeloid leukemia discovery may benefit patients

A new study led by Ze'ev Ronai, Ph.D., has shown that the protein RNF5 plays an unusual role in acute myeloid leukemia (AML). Unlike its expected role, marking aberrant proteins for destruction, RNF5 binds with a second cell protein called RBBP4 to control expression of genes implicated in AML. These findings, published in Nature Communications, have important implications for improving AML patient outcomes.

2021 Fishman Fund Award Ceremony celebrates postdoctoral scholars 

The Fishman Fund Awards were presented on September 23, 2021, in a virtual ceremony that honored the enduring legacy of our Institute’s founders, Dr. William and Lillian Fishman. The three exceptional winners were welcomed by Fishman Fund co-founder Reena Horowitz; co-founder designee Jeanne Jones; and 2018 award recipient Laura Martin-Sancho, who commented, “A Fishman Fund Award is more than the money—it means that someone believes in you and believes in your goals.”

Personalizing medicine for pediatric brain cancer

Medulloblastoma is the most common malignant brain tumor in children. Safer and more effective therapies are desperately needed, and advances cannot come soon enough. Join us on Tuesday, October 12, from 1:00 to 2:00 p.m. PT, to learn about the latest efforts to develop better treatments for pediatric brain cancer.

Pancreatic cancer remains one of the deadliest cancers for which there is no current effective treatment. Join us on Wednesday, November 17, from 1:00 to 2:00 pm PT, to learn about promising research breakthroughs toward effective treatments for pancreatic cancer.

Updates On: Clinical Trials

Join Keith T. Flaherty, M.D., director of Clinical Research at Massachusetts General Hospital Cancer Center, and Ze'ev Ronai, Ph.D., director of the NCI-designated Cancer Center at Sanford Burnham Prebys, on Monday, October 25, from 12:00 to 1:00 pm PT, to learn about the important role clinical trials play in advancing new treatments for cancer. The event will be hosted by Steven Silverstein, patient advocate and former president of the Melanoma Research Foundation.

A Look Inside the Lab: Researching Breast Cancer

About 1 in 8 women will be diagnosed with an invasive form of the breast cancer over the course of her lifetime. How are researchers working to stop these trends and save the lives of those with breast cancer? Hear from Dr. Svasti Haricharan's lab, on scientific advances to help battle breast cancer.

At Sanford Burnham Prebys, we're passionate about finding bold new ways to treat disease, and we recognize the importance of sharing our discoveries with the public—especially during this unprecedented time. Find out where and when you can "meet" our scientists virtually and learn about their research in this community event calendar.
Please Donate
Donate now

Please join Sanford Burnham Prebys as a partner in discovery. Our world-class research programs are dedicated to finding cures for human disease to help individuals and their families. Your gift helps our scientists advance medical research to save lives. 
Could you benefit from the CARES Act of 2020?

The CARES Act of 2020 offers a once-in-a-lifetime opportunity to make transformative philanthropic gifts, with significant tax benefits to you and your family. Cash gifts to charities such as Sanford Burnham Prebys are deductible at 100% of adjusted gross income.